Phenotypic and genotypic characteristics of tetracycline resistant *Acinetobacter baumannii* isolates from nosocomial infections at Tehran hospitals

Mohammad Hossein Maleki 1, Zamberi Sekawi 2, Setareh Soroush 1, 3, Parid Azizi-Jalilian 1, 2, Khaireollah Asadollahi 4, Sattar Mohammadi 3, Mohammad Emaneini 5, Morovat Taherikalani 1, 2 *

1 Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran
2 Department of Medical Microbiology and Parasitology, Faculty of Medicine and Health Sciences, University of Putra, Malaysia
3 Department of Microbiology, School of Medicine, Ilam University of Medical Sciences, Ilam, Iran
4 Psychosocial Injuries Research Center, Ilam University of Medical Sciences, Ilam, Iran
5 Department of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

**ABSTRACT**

**Objective(s):** To date, the most important genes responsible for tetracycline resistance among *Acinetobacter baumannii* isolates have been identified as tetA and tetB. This study was carried out to determine the rate of resistance to tetracycline and related antibiotics, and mechanisms of resistance.

**Materials and Methods:** During the years 2010 and 2011, a total of 100 *A. baumannii* isolates were isolated from different hospitals of Tehran, Iran. Antimicrobial susceptibility to tetracycline, minocycline, doxycycline and tigecycline was evaluated by E-test. Polymerase chain reaction (PCR) of the tetA and tetB genes was performed using specific primers, after which the isolates were subjected to Repetitive Extragenic Palindromic-PCR (REP-PCR) to identify the major genotypes.

**Results:** Of all isolates, 89% were resistant to tetracycline (MIC\(_{90} = 32 \mu g/ml\), MIC\(_{50} = 512 \mu g/ml\)). Minocycline with the resistant rate of 35% (MIC\(_{90} = 16 \mu g/ml\), MIC\(_{50} = 32 \mu g/ml\)) and doxycycline with the resistant rate of 25% (MIC\(_{90} = 16 \mu g/ml\), MIC\(_{50} = 32 \mu g/ml\)) have a good activity against *A. baumannii* isolates. All isolates were sensitive to tigecycline. Frequencies of tetB and tetA genes and coexistence of tetA and tetB among the isolates resistant to tetracycline, were 87.6%, 2.2% and 1.1%, respectively. Distribution of REP-types among *A. baumannii* isolates was types A (40%), B (30%), C (10%), D (5%) and E (5%).

**Conclusion:** It seems that tetA and tetB genes play an important role in the induction of resistance towards tetracyclines used in this study. It is suggested that further studies focus on other antimicrobial drugs and combinations in order to achieve a successful therapy against multi drug resistance (MDR) *A. baumannii* strains in Iran.

**Introduction**

*Acinetobacter baumannii* is the most clinically important species in the Acinetobacter genus that is involved in 1-2% of nosocomial pneumonia primarily in debilitated patients (1, 2). Infections due to *A. baumannii*, especially multi drug resistant strains, have been reported worldwide, so that only a few antibiotics have remained effective against MDR strains.

Resistance against aminopenicillins, ureidopenicillins, cephalosporins, cephemycins, aminoglycosides, chloramphenicol, tetracyclines, fluoroquinolones and carbapenems were initially reported from different parts of the world (2). Tetracycline is a bacteriostatic antibiotic which inhibits protein synthesis by preventing the attachment of aminocyl-tRNA to the ribosomal acceptor site. To date, the main mechanisms responsible for tetracycline resistance have been identified as (i) expression of efflux pumps and (ii) ribosomal protection. *tetA* and *tetB* are the most extensively characterized genes responsible for ribosomal protection. Although the distribution of many genes

*Corresponding author: Morovat Taherikalani. Clinical Microbiology Research Center and Department of Microbiology, School of Medicine, Ilam University of Medical Sciences, Banganganj, Ilam, Iran. Tel: +98-841-2235747; Fax: +98-841-2227136; email: taherikalani@gmail.com
responsible for resistance towards antimicrobial agents especially carbapenems and aminoglycosides, has been previously reported among A. baumannii isolates in Iran (3-12).

There appears to be no comprehensive data concerning the mechanisms of resistance towards tetracycline and related antibiotics among A. baumannii isolates in this country. The aim of the present study was, therefore, to analyze the molecular mechanisms of resistance towards tetracycline and related antibiotics among clinical isolates of A. baumannii and to estimate the prevalence of the genetic constructs containing tet A and tet B genes in the isolates of this microorganism. Furthermore, the susceptibility of the isolates towards tigecycline (as a glycyclcycline and a derivative of minocycline) and tetracyclines including tetracycline, minocycline and doxycycline was surveyed in this study.

Materials and Methods

Study population
A total of 100 non-repetitive A. baumannii isolates were recovered in years 2010 and 2011 from patients in different hospitals of Tehran, Iran. The isolates were non-repetitive, meaning that each isolate was obtained from a particular patient and each patient was sampled only once. These isolates were cultured from wounds (n = 40), the trachea (n = 30), blood (n = 10), urine (n = 15), and catheter (n = 5). Strains were isolated mainly from patients in intensive care units (n = 36), burned ward (n = 30), internal ward (n = 20) and surgery (n = 4) from eight hospitals in Tehran, Iran.

All the isolates were identified as A. baumannii by the detection of blaOXA-51-like, an intrinsic and species specific gene, using API 20NE and biochemical testing according to those reported in previous reports (13).

Antimicrobial susceptibility
Using E-test, the susceptibility of all the isolates toward tetracycline, minocycline, doxycycline and tigecycline was tested. The isolates were then interpreted according to the manufacturer instructions and CLSI guidelines (14). Escherichia coli, ATCC 25922 and Pseudomonas aeruginosa, ATCC 27852 were used as internal control. MIC interpretative standards for together tetracycline, minocycline and doxycycline was S: ≤ 4 μg/ml, I: 8 μg/ml and R: ≥16 μg/ml, respectively. The criteria defined by the US Food and Drug Administration (FDA) for Enterobacteriaceae were used for tigecycline (s2, ≥4 μg/ml for susceptible and non susceptible strains, respectively) (15).

DNA extraction
Strains were maintained at -70°C in 80% /20% (v/v) glycerol in LB medium to preserve genetic variation during storage and were grown overnight on MacConkey agar at 37°C. DNA extraction was carried out by DNA Extraction kit (BIONER, Republic of Korea) in accordance with the manufacturer instructions. DNA was stored at -20°C until further use.

PCR amplification of tet A and tet B genes
The PCR products for tet A and tet B genes were considered presumptive positive based on ampiclon sizes of 164bp and 206 bp, respectively. In the case of a negative PCR, PCR amplifications were repeated at least twice for these genes. A negative control was run along each PCR.

The primer sequences included tet A (F: 5’-GCG CGATCTGGTTCACTCG-3’; R: 5’-AGTCGACAGYRGCG CCGGC-3’ and tet B (F: 5’-CGTGAATTATTCTT CGG-3’; R: 5’-ATACAGCATCCAAAGCGAC-3’) (16). PCR were performed in a final volume of 25 μl containing 1X PCR buffer, 2 mM MgCl₂, 2 mM dNTPs, 10 pmol of primers, 0.25 U Taq DNA polymerase (Fermentas, UK) and 5 μl of template DNA.

PCR conditions included 30 cycles of amplification under the following conditions: denaturation at 95°C for 30 s, annealing at 56°C for 1 min, and extension at 72°C for 1 min/kb product. Cycling was followed by a final extension at 72°C for 10 min. PCR products were resolved on 1.0% agarose gels, stained with ethidium bromide, and photographed with UV illumination. The 100-bp DNA ladder was used to assess PCR product size.

REP-PCR
All the isolates were subjected to REP-PCR typing method for finding common REP-types among all of the isolates. The primers used for REP-typing include F: 5’-IIIIGCGCCGICATCACGGGC-3’ and R: 5’-AGCTCTTATCCAGGCTAC-3’ (17). Amplification reaction was performed in a final volume of 25μl. The reaction contain 2.5 μl of 10X PCR buffer, 1.25U Taq DNA polymerase (Fermentas, UK), 0.8 μl of 2 mM mixed dNTP,1.5 μl of 25 mM MgCl₂, 1 μl of 10 pmol of primers and 5 μl of template DNA. Amplification reaction was carried out by thermal cycler (Eppendorf, Germany) with an initial denaturation at 94°C for 10 min, followed by 30 cycles of denaturation at 94°C for 1 min, annealing at 45°C for 1 min, and extension at 72°C for 1 min, followed by final extension at 72°C for 16 min. Samples (20 μl) of each PCR end-product were analysed on agarose 2% w/v gels.

Results
Tigecycline, being effective against all tested A. baumannii isolates (100/100), was the most effective antimicrobial agent with the MIC₅₀ = 0.125 μg/ml to MIC₉₀ = 2 μg/ml. Resistance rate against doxycycline, minocycline and tetracycline was 18%, 19% and 80%, respectively (Table 1, 2). Totally, 50 % (n =
50/100) and 4% (n = 4/100) of all the strains were only resistant to tetracycline and minocycline, respectively. Resistance rates of combinations of tetracycline + minocycline, tetracycline + minocycline + doxycycline, tetracycline + doxycycline, and minocycline + doxycycline were 16% (n = 16/100), 13% (n = 13/100), 10% (n = 10/100) and 2% (n = 2/100), respectively. Among the isolates, 4% (n = 4/100; 4%) were sensitive to all the antibiotics used in this study whilst 96% (n = 96/100; 96%) were resistant to at least one antibiotic among which 13% (n = 13/96; 13.54%) were resistant to all the antibiotics used in this study. Among the resistant isolates, 36% (n = 36/96; 37.5%) were resistant to at least one resistance gene. Tet B was the most frequent encoding gene among tetracycline resistant A. baumannii strains (n = 78/89; 87.6%) and minocycline resistant A. baumannii isolates (n = 11/35; 31.4%) and doxycycline (n = 10/25; 40%) resistant A. baumannii isolates (Table 3). Coexistence of tet A + tet B was seen among 1.1% (1 out of 80) of the tetracycline resistant isolates, 13.2% (5 out of 16) of the minocycline resistant and 44.4% (8 out of 18) of the doxycycline resistant A. baumannii isolates. According to Table 3, less than 50% of intermediate isolates (intermediate resistance to tetracycline: 44.4%, intermediate resistance to minocycline: 31.2% and intermediate resistance to doxycycline: 28.5%) harbored tet B gene (Table 3). REP-PCR showed five clusters A, B, C, D and E with distribution rates of 40% (n = 40/100), 30% (n = 30/100), 10% (n = 10/100), 5% (n = 5/100) and 5% (5/100) among tetracycline resistant A. baumannii isolates, respectively. The REP patterns between ten A. baumannii isolates could not be distinguished by REP-fingerprinting (Dendrograme 1).

**Discussion**

The current study can be considered as the first comprehensive study evaluating tetracycline resistant A. baumannii isolates containing tet A and tet B resistance determinants in different hospital of Tehran, Iran.

In most clinical practices, tetracyclines are not commonly used as treatments against A. baumannii infections due to the lack of data demonstrating their therapeutic efficacy. As a result, tetracycline resistance is not routinely monitored for multidrug resistant A. baumannii and very few data are available on the phenotypic and genotypic characterization of resistance against these bacteriostatic agents among A. baumannii strains in Iran. Limited data was previously reported regarding tetracycline resistance among A. baumannii strains isolated from burn patients in one educational hospital in Tehran, Iran (6, 8, 12). The current study was, however, carried out in different hospitals and different samples.

Most of the A. baumannii strains in this study (n = 89/100; 89%) were tentatively classified as tetracycline resistant based on an E-test (MIC$_{50}$ = 32µg/ml).

### Table 1. Antimicrobial susceptibility patterns of tetracycline and related antibiotic against Acinetobacter baumannii isolates

<table>
<thead>
<tr>
<th>Antibiotics</th>
<th>MIC ranges of MIC</th>
<th>MIC$_{50}$ (µg/ml)</th>
<th>MIC$_{90}$ (µg/ml)</th>
<th>Sensitive</th>
<th>Intermediate</th>
<th>Resistant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tigecycline</td>
<td>0.125-2</td>
<td>0.5</td>
<td>2</td>
<td>100 (%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Tetracycline</td>
<td>0.125-512</td>
<td>32</td>
<td>512</td>
<td>11 (11%)</td>
<td>9 (9%)</td>
<td>80 (80%)</td>
</tr>
<tr>
<td>Minocycline</td>
<td>0.125-512</td>
<td>16</td>
<td>32</td>
<td>65 (65)</td>
<td>16 (16)</td>
<td>19 (19%)</td>
</tr>
<tr>
<td>Doxycycline</td>
<td>0.125-512</td>
<td>16</td>
<td>32</td>
<td>75 (75)</td>
<td>7 (7)</td>
<td>18 (18%)</td>
</tr>
</tbody>
</table>

### Table 2. MIC value of antibiotics against Acinetobacter baumannii isolates

<table>
<thead>
<tr>
<th>Antibiotics</th>
<th>MIC diluted (µg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tetracycline</td>
<td>0.125 0.25 0.5 1 2 4 8 16 32 64 128 256 512</td>
</tr>
<tr>
<td>Minocycline</td>
<td>10 5 5 10 16 19 16 3 5 2 2 3 4</td>
</tr>
<tr>
<td>Doxycycline</td>
<td>8 14 12 17 9 8 7 2 5 2 2 2 5</td>
</tr>
<tr>
<td>Tigecycline</td>
<td>21 31 28 10 10 0 0 0 0 0 0 0 0</td>
</tr>
</tbody>
</table>

### Table 3. Distribution of tetracycline resistance genes among Acinetobacter baumannii isolates regarding different antibiotics

<table>
<thead>
<tr>
<th>Gene/s</th>
<th>Tetracycline n (%)</th>
<th>Minocycline n (%)</th>
<th>Doxycycline n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>tetA</td>
<td>I (n=9)</td>
<td>R (n=80)</td>
<td></td>
</tr>
<tr>
<td>tetB</td>
<td>4 (44.4)</td>
<td>74 (83.1)</td>
<td>6 (31.2)</td>
</tr>
<tr>
<td>tetA + tetB</td>
<td>0 (0)</td>
<td>5 (26.3)</td>
<td>2 (28.5)</td>
</tr>
<tr>
<td>None</td>
<td>5 (55.5)</td>
<td>3 (3.7)</td>
<td>5 (26.3)</td>
</tr>
</tbody>
</table>
and MIC\textsubscript{90} = 512 µg/ml). Resistance of the isolates was subsequently confirmed by MIC values of ≥16 µg/ml, which is the proposed clinical breakpoint of CLSI to define resistance against tetracycline, minocycline and doxycycline.

In this study, like the report from Iran (18), all of the isolates were sensitive to tigecycline, however, in recent reports from Iran, tetracycline resistant \textit{A. baumannii} isolates was reported from Tehran and Tabriz (15, 19).

Tigecycline is a novel expanded broad-spectrum glyyclcycline antibiotic that has a good activity against isolates which are either resistant and/or sensitive to tetracycline, minocycline and doxycycline. It seems that the activity of tigecycline is not affected by the tetracycline resistance mechanisms described above. Although resistance to tigecycline is not seen among \textit{A. baumannii} isolates, it has been recently shown that resistance against these antibiotics may exist due to the over expression of AdeABC efflux pump (20-22). Both tigecycline highly resistant and sensitive \textit{A. baumannii} have been reported from all over the world (22, 23).

Being highly resistant to tetracycline is common among \textit{A. baumannii} isolates and the result of this study confirmed those data (24).

Activity of doxycycline in our Iranian \textit{A. baumannii} isolates is in line with the reports from European countries. Mezzatesta and collageous also found that 94% of the isolates were sensitive to doxycycline (22).

Likewise, Pei \textit{et al} reported high degree of sensitivity to minocycline. We also found minocycline has a moderate activity against \textit{A. baumannii} isolates with the sensitivity rate of 65% (25). The result of Denis \textit{et al} study which showed MDR \textit{A. baumannii} isolates in USA, were susceptible to tigecycline and minocycline in consistency with our results (26).

The results, however, suggested a higher prevalence of the \textit{tet B} gene among these clinical isolates (n = 78/89; 87.6%). These results are consistent with those of Guardabassi \textit{et al}, who found that \textit{tet A} and \textit{tet B} are the genes responsible for tetracycline resistance (27).

The results of this study, therefore, supports these data, since the \textit{tet A} gene was identified in the strains resistant to tetracycline but not in those resistant to minocycline, whilst the gene was not found in the strains resistant to both antibiotics (28). These strains may possess the \textit{tet B} determinant, which would confer with the resistance to both antibiotics. The genes \textit{tet A} and \textit{tet B} were not detected in 22 clinical isolates of tetracycline resistant \textit{A. baumannii}. Tetracycline resistance in these isolates is probably due to other resistance genes and efflux pumps (29). REP-patterns could not be distinguished in ten of the isolates studied. Furthermore, only five clusters were identified among the \textit{A. baumannii} isolates. Patterns of resistance and distribution of \textit{tet A} and \textit{tet B} genes among different cluster were different. It seems that \textit{A. baumannii} molecular typing via PCR-based methods
such as REP, could be beneficial in the differentiation of different strains of A. baumannii (30-33). Despite the increased frequency of multidrug resistance among the A. baumannii strains from Iran, only a little information exists regarding the antimicrobial resistance of this Gram negative bacillus in Tehran, Iran. The results of this study confirms those of the previous study which was carried out only on burn patients and which reported tet A and tet B as the most frequent mechanisms of tetracycline resistance among Iranian A. baumannii isolates. The identification of tet A and tet B in this study also confirms the wide geographical distribu- tion of these resistance genes among tetracycline resistant A. baumannii strains. The results show that surveillance for multidrug resistant A. baumannii should be maintained and careful infection control and cautious use of antibiotics must be taken into consideration.

Ethics
This study received approval from Ilam University of Medical Sciences Ethics Committee, Ilam, Iran.

Acknowledgment
This work was supplied by Ilam University of Medical Sciences, Ilam, Iran. We gratefully thank all the staff of Department of Medical Microbiology of Ilam, especially Mr. Ali Hematic for all supports during this project.

References

Iran J Bas Med Sci. Vol. 17, No.1, Jan 2014


